French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal marks a loss of sovereignty over key medications.
Paris "must block the sale" using powers to protect strategic sectors, said Manuel Bompard, a senior lawmaker in hard-left France Unbowed (LFI), in an interview with broadcaster TF1.
